The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

Cathcart A.L., Havenar-Daughton C., Lempp F.A., Ma D., Schmid M.A., Agostini M.L., Guarino B., Di iulio J., Rosen L.E., Tucker H., Dillen J., Subramanian S., Sloan B., Bianchi S., Pinto D., Saliba C., Culap K., Wojcechowskyj J.A., Noack J., Zhou J., Kaiser H., Lee S., Farhat N., Chase A., Montiel-Ruiz M., Dellota E., Park A., Spreafico R., Sahakyan A., Lauron E.J., Czudnochowski N., Cameroni E., Ledoux S., Kawaoka Y., Werts A., Colas C., Soriaga L., Telenti A., Purcell L.A., Hwang S., Snell G., Virgin H.W., Corti D., Hebner C.M.
Publication typePosted Content
Publication date2021-03-10
Abstract
ABSTRACT

Sotrovimab (VIR-7831) and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Sotrovimab and VIR-7832 were derived from a parent antibody (S309) isolated from memory B cells of a 2003 severe acute respiratory syndrome coronavirus (SARS-CoV) survivor. Both mAbs contain an “LS” mutation in the Fc region to prolong serum half-life. In addition, VIR-7832 encodes an Fc GAALIE mutation that has been shown previously to evoke CD8+ T-cells in the context of an in vivo viral respiratory infection. Sotrovimab and VIR-7832 neutralize wild-type and variant pseudotyped viruses and authentic virus in vitro. In addition, they retain activity against monoclonal antibody resistance mutations conferring reduced susceptibility to previously authorized mAbs. The sotrovimab/VIR-7832 epitope continues to be highly conserved among circulating sequences consistent with the high barrier to resistance observed in vitro. Furthermore, both mAbs can recruit effector mechanisms in vitro that may contribute to clinical efficacy via elimination of infected host cells. In vitro studies with these mAbs demonstrated no enhancement of infection. In a Syrian Golden hamster proof-of concept wildtype SARS-CoV-2 infection model, animals treated with sotrovimab had less weight loss, and significantly decreased total viral load and infectious virus levels in the lung compared to a control mAb. Taken together, these data indicate that sotrovimab and VIR-7832 are key agents in the fight against COVID-19.

Top-30

Citations by journals

1
2
3
4
5
6
Viruses
6 publications, 3.37%
Nature
6 publications, 3.37%
Frontiers in Immunology
5 publications, 2.81%
Science
5 publications, 2.81%
Scientific Reports
4 publications, 2.25%
Journal of Biomedical Science
3 publications, 1.69%
BMC Infectious Diseases
3 publications, 1.69%
Microbiology spectrum
3 publications, 1.69%
Infection
3 publications, 1.69%
Infectious Diseases and Therapy
2 publications, 1.12%
Nature Medicine
2 publications, 1.12%
Journal of Clinical Medicine
2 publications, 1.12%
Clinical Microbiology Reviews
2 publications, 1.12%
International Journal of Biological Macromolecules
2 publications, 1.12%
Canadian Journal of Chemistry
1 publication, 0.56%
Journal of Pharmaceutical Innovation
1 publication, 0.56%
Biochemical Society Transactions
1 publication, 0.56%
BMJ Open
1 publication, 0.56%
Nursing
1 publication, 0.56%
Pharmaceuticals
1 publication, 0.56%
Vaccines
1 publication, 0.56%
International Journal of Molecular Sciences
1 publication, 0.56%
Antibodies
1 publication, 0.56%
Biomedicines
1 publication, 0.56%
Microbial Cell Factories
1 publication, 0.56%
Nature Reviews Genetics
1 publication, 0.56%
Cell Discovery
1 publication, 0.56%
npj Vaccines
1 publication, 0.56%
Signal Transduction and Targeted Therapy
1 publication, 0.56%
1
2
3
4
5
6

Citations by publishers

5
10
15
20
25
30
35
40
45
50
Cold Spring Harbor Laboratory
46 publications, 25.84%
Springer Nature
44 publications, 24.72%
Elsevier
20 publications, 11.24%
Multidisciplinary Digital Publishing Institute (MDPI)
15 publications, 8.43%
Wiley
7 publications, 3.93%
American Association for the Advancement of Science (AAAS)
7 publications, 3.93%
American Society for Microbiology
7 publications, 3.93%
Taylor & Francis
6 publications, 3.37%
Frontiers Media S.A.
5 publications, 2.81%
BMJ
3 publications, 1.69%
American Chemical Society (ACS)
3 publications, 1.69%
Oxford University Press
2 publications, 1.12%
Canadian Science Publishing
1 publication, 0.56%
Portland Press
1 publication, 0.56%
Wolters Kluwer Health
1 publication, 0.56%
Rockefeller University Press
1 publication, 0.56%
eLife Sciences Publications
1 publication, 0.56%
Annual Reviews
1 publication, 0.56%
Bentham Science
1 publication, 0.56%
Public Library of Science (PLoS)
1 publication, 0.56%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.56%
5
10
15
20
25
30
35
40
45
50
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Found error?